A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Completed · Phase 1/Phase 2

Conditions studied: Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC

In brief

This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for whom there is no standard therapy. After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) tumors.

Key facts

Study ID: NCT01262235
Run by: Arbutus Biopharma Corporation
People needed: 68
Starts: 2010-12-01
Expected to finish: 2015-08-01
Last updated by the study team: 2019-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have a histologically and cytologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy is known to exist, or who are not candidates for standard therapy, or non-Hodgkin's lymphoma or Hodgkin's disease that is refractory to standard therapy (i.e., patients have relapsed following at least 2 prior therapies) or for which no standard therapy is known to exist. For the Neuroendocrine (NET) and adrenocortical carcinoma (ACC) expansion cohort subjects must have histologically or cytologically confirmed, measurable (per RECIST 1.1) NET or ACC tumor that is refractory to standard therapy or for which no standard therapy is known to exist, or who are not candidates for standard therapy.
Patient has an ECOG performance status of 0 - 1,
Patient has adequate hematologic, hepatic and renal function,
Patient is seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV),
Patients must have a life expectancy of at least 12 weeks.

You may not qualify if…

Unresolved toxicities (> Grade 1) of previous chemotherapy,
Patients with primary tumors of the central nervous system (CNS),
Prophylactic hematologic growth factors administered </= 2 weeks prior to start of therapy,
Patient has history of or existing clinically significant cardiovascular disease,
Patient has a history of clinically significant asthma or COPD requiring daily medication within the last 6 months,
Patient has a seizure disorder not controlled on medication,
Patient has a known or suspected viral, parasitic, or fungal infection,
Patient has known hypersensitivity or previous severe reactions to oligonucleotide- or lipid-based products, including liposomal drug products and phospholipid-based products,
Patient has been treated with any investigational drugs, biologics, or devices within 28 days prior to study treatment.

Where it is running

Scottsdale Healthcare Research Institute — Scottsdale, Arizona, United States
Mayo Clinic Arizona — Scottsdale, Arizona, United States
Moffitt Cancer Center — Tampa, Florida, United States
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa, United States
Dana Farber Cancer Institute — Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
Mayo Clinic — Rochester, Minnesota, United States
Westchase Oncology Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.